Anti-MDA5 positive dermatomyositis associated with rapidly progressive interstitial lung disease and correlation between serum ferritin level and treatment response

Daniela Noa Zohar*, Lior Seluk, Hagith Yonath, Yehuda Shoenfeld, Shaye Kivity

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Clinically amyopathic dermatomyositis is an uncommon autoimmune disorder in the Middle East. The clinical picture of clinically amyopathic dermatomyositis is characterized mainly by pulmonary and dermatological manifestations. Occasionally muscle symptoms are observed as well. Serum anti-MDA5 autoantibody positivity is associated with rapidly progressive interstitial lung disease among clinically amyopathic dermatomyositis patients. Moreover, high serum ferritin level is correlated with poor prognosis and high mortality. Herein we describe the case of an Israeli patient with rapidly progressive interstitial lung disease and without pathognomonic dermatological features who was diagnosed with anti-MDA5 positive clinically amyopathic dermatomyositis and did not survive despite immunomodulatory therapy followed by reduction in serum ferritin levels.

Original languageEnglish
Article number75
Pages (from-to)75-77
Number of pages3
JournalMediterranean Journal of Rheumatology
Volume31
Issue number1
DOIs
StatePublished - 1 Mar 2020

Keywords

  • Anti-MDA5
  • Clinically amyopathic dermatomyositis
  • Hyperferritinemia
  • Interstitial lung disease
  • MSA

Fingerprint

Dive into the research topics of 'Anti-MDA5 positive dermatomyositis associated with rapidly progressive interstitial lung disease and correlation between serum ferritin level and treatment response'. Together they form a unique fingerprint.

Cite this